Navigation Links
Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease
Date:7/17/2008

the Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine in Houston. "There is a clear need for new treatments that can add value and enduring benefit to the treatment of Alzheimer's disease. The results of this trial suggest that, if the findings are replicated, Dimebon could advance Alzheimer's treatment, offering more hope for patients and their caregivers."

Dimebon was well-tolerated throughout the trial. There was no difference between the Dimebon and placebo groups in the number of patients with adverse events, and the most common side effects seen were dry mouth (18 percent versus 1 percent for placebo) and depressed mood/depression (15 percent versus 5 percent for placebo). Importantly, fewer patients treated with Dimebon had serious adverse events than did patients on placebo at the end of the study (3 percent versus 12 percent; p=0.03).

Additional analyses of the Dimebon pivotal study data presented at recent medical conferences showed that Dimebon's impact extended to caregivers. Behavioral improvements in Dimebon-treated patients resulted in a significant decrease in caregiver distress at six months and at one year compared to the distress of caregivers of placebo-treated patients. Further, after six months, caregivers of Dimebon-treated patients saved approximately one hour per day assisting patients with activities of daily living compared to caregivers of placebo-treated patients.

"The magnitude, consistency and duration of the beneficial effects of Dimebon demonstrated in this trial are striking," said Paul Aisen, M.D., Director, Alzheimer's Disease Cooperative Study (ADCS) and Professor in the Department of Neurosciences, University of California, San Diego (UCSD). "In addition, the drug has been well-tolerated to date and, if the safety profile is replicated in the ongoing international trial, it will be a substantial advance for this patient population prone to drug side effects."

"We are pleased
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
2. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
3. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
4. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
7. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
8. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
11. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... BROOKFIELD, Wis. , March 27, 2015 /PRNewswire/ ... 40,000 unit shipments of incontinence devices for women. ... terrific, but the most gratifying part is the ... receive from women whose lives have been positively ... , president of InControl. InControl recently ...
(Date:3/27/2015)... 27, 2015 RnRMarketResearch.com adds ... market research report of 52 pages with latest ... intelligence library. The report "Visceral Pain - Pipeline ... therapeutic development for Visceral Pain, complete with comparative ... target, mechanism of action (MoA), route of administration ...
(Date:3/26/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... therapies for cardiovascular disease and overall health, announced that ... of the Corporation (the "Common Shares"). The Common Shares ... 5 th , 2014 to March 4 th , ... on or before April 1, 2015. Interest on the ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... Pa., Oct. 22 Cephalon, Inc. (Nasdaq: ... Strategies (REMS) for its medications NUVIGIL® (armodafinil) Tablets [C-IV] ... the U.S. Food and Drug Administration (FDA).  Both the ... to inform patients about the potential risks associated with ...
... China, Oct. 22 /PRNewswire-Asia-FirstCall/ -- China Medicine Corporation ... Medicine" or "the Company"), a leading manufacturer, developer ... ("TCM"), and other health products, today announced that ... financial results after market close on Wednesday, November ...
Cached Medicine Technology:Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL 2Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL 3Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL 4
(Date:3/28/2015)... Centurion Service Group will be hosting a live ... at their Las Vegas warehouse, located at 4606 Andrews St. ... consists of equipment from hospitals and surgery centers from around ... , Buyers will find items of all types including ... one-stop-shop,” said Erik Tivin, CEO of Centurion. , Among the ...
(Date:3/28/2015)... Early surgery may not be the ... joint injuries, according to new research from Tripler Army ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Specialty ... surgery was not performed. , The final study group ... and 17 receiving non-surgical therapy. Of the non-surgery group, ...
(Date:3/28/2015)... 28, 2015 Healthpointe’s otolaryngologists, medical practitioners ... throat disorders, are now offering a wide variety ... which is characterized by the presence of phantom sounds ... people, tinnitus is a prevalent symptom that can arise ... is non-fatal, tinnitus can impede a person’s quality of ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
(Date:3/27/2015)... FL (PRWEB) March 27, 2015 Florida Hospital ... Storm as the team’s exclusive health care provider for the ... provider, Florida Hospital provides medical care and an athletic trainer ... Storm will kick off its season against the Cleveland Gladiators ... , “This partnership is extremely important to us as it ...
Breaking Medicine News(10 mins):Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3
... M. Jackson Foundation for the Advancement of Military Medicine, ... the Health Sciences (USU) doctoral students to receive fellowships ... 1988, includes two Henry M. Jackson Fellowships and one ... and travel support. Jeremy Gilbreath, a ...
... A broad panel of leaders representing health care, academic ... in the content and format of U.S. graduate medical ... effectively and efficiently to meet public needs. ... for overhauling the training of newly minted physicians - ...
... of the University of California and a Southern California ... commercialize their ideas for new, lower cost health care ... affordable and efficient chronic disease management and preventive health ... is led by the von Liebig Entrepreneurism Center at ...
... health plans nationally may benefit consumers by lowering hospital ... are the most consolidated, according to a new RAND ... about 12 percent lower in the metropolitan areas ... view that when health plans become bigger they can ...
... usually reserved for designing buildings, bridges and aircraft has ... cancer patients. In a study published today, ... , researchers used computer-aided design (CAD) to create an ... as a visual aid to surgeons in tissue reconstruction ...
... ROCHESTER, Minn. -- A study by Mayo Clinic physician and ... Sandhya Pruthi, M.D. , and colleagues found that flaxseed ... among breast cancer patients and postmenopausal women. The study is ... Menopause . The randomized, placebo-controlled study followed ...
Cached Medicine News:Health News:HJF names 2011-12 fellowship award winners 2Health News:Macy Foundation report calls for sweeping graduate medical education reforms 2Health News:Macy Foundation report calls for sweeping graduate medical education reforms 3Health News:Macy Foundation report calls for sweeping graduate medical education reforms 4Health News:Accessible and affordable care at heart of health-care technology grants 2Health News:Accessible and affordable care at heart of health-care technology grants 3Health News:Accessible and affordable care at heart of health-care technology grants 4Health News:Accessible and affordable care at heart of health-care technology grants 5Health News:Accessible and affordable care at heart of health-care technology grants 6Health News:Accessible and affordable care at heart of health-care technology grants 7Health News:Consolidation of health plans may help lower hospital costs, study finds 2Health News:Computer-aided design used for breast tissue reconstruction 2Health News:Flaxseed no help for hot flashes during breast cancer or menopause, study finds 2
... immunosorbent assay method for the semi-quantitative determination ... human serum. The results of the anti-Gliadin ... aid in the diagnosis of diseases associated ... Coeliac Disease. Levels of these autoantibodies are ...
... a high throughput primary or backup ... offers performance and reliability equal to ... instruments. The advanced technology of the ... strips delivers reproducible and accurate results, ...
... assay was originally developed for the World ... ovarian function. It has been widely used ... of natural family planning methods. Urine samples ... concentration measured by EIA (enzyme labelled immunoassay ...
... 10-8700 ACTIVE® Estrone Enzyme Immunosorbent Assay ... quantitative measurement of Estrone in serum. ... of enzyme immunoassay where there is ... an enzyme-labeled antigen for a fixed ...
Medicine Products: